CereGate Therapy to Reduce Freezing of Gait in Parkinson’s Disease

Summary

The purpose of this study is to determine whether using CereGate therapy with deep brain stimulation (DBS) reduces freezing of gait in individuals diagnosed with Parkinson’s Disease (PD) who have been implanted with a Boston Scientific Gevia DBS system. Gait freezing involves the involuntary halting of motor (body movement) activity. The investigational device (CereGate Therapy) provides a “cue” to reduce freezing of gait in Parkinson’s disease by using electricity to activate brain areas next to those activated by DBS. Study procedures include collection of symptoms information, completion of freezing and falls diary, completion of assessments and evaluations, and collection of vital signs.


Inclusion Criteria

  • Participant has implanted Boston Scientific Gevia STN-DBS system
  • Participant is receiving treatment with carbidopa/levodopa, and/or with a dopamine agonist at the optimal doses as determined by a movement disorders neurologist.
  • DBS optimized with documented improvement in motor signs (UPDRSIII) from DBS
Show more

Study Location(s)

Beverly

More about this Clinical Trial

Full Title

A Multi-Center, Controlled Study to Evaluate use of CereGate Therapy to Reduce Freezing of Gait in Participants diagnosed with Parkinson?s Disease

Details
Disease Type/Condition

Other

Principal Investigator

Tagliati, Michele

Co-Investigators

Echo Tan, Elliot Hogg

Age Group

Adult

Phase

N/A

IRB Number

STUDY00002036

ClinicalTrials.gov ID

NCT05292794

Key Eligibility
ClinicalTrials.gov

Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?

Details
Disease Type/Condition

Other

Principal Investigator

Tagliati, Michele

Age Group

Adult

Phase

N/A

IRB Number

CG-001

ClinicalTrials.gov ID

NCT05292794

Key Eligibility
ClinicalTrials.gov

Contact
Phone
310-423-6252
Email
clinicaltrials@cshs.org
Want to join the study or
learn more?